Browsing: CAR-T cell therapy

Recent advances in CAR T-cell therapy have shown great promise in cancer treatment, but affordability remains a challenge. This article explores how localising key components and scaling production can make this life-saving therapy more accessible.

AbClon has signed an exclusive technology transfer agreement with TCT Health Technology, a Turkish company, for its CAR-T cell therapy, AT101. The deal grants TCT exclusive rights in Turkey and includes upfront and milestone payments for AbClon.